Gürkan Hakan, Atli Emine İkbal, Atli Engin, Bozatli Leyla, Altay Mengühan Araz, Yalçintepe Sinem, Özen Yasemin, Eker Damla, Akurut Çisem, Demır Selma, Görker Işık
Faculty of Medicine, Department of Medical Genetics, Edirne, Trakya University, Edirne, Turkey.
Faculty of Medicine, Department of Child and Adolescent Psychiatry, Trakya University, Edirne, Turkey.
Noro Psikiyatr Ars. 2020 May 5;57(3):177-191. doi: 10.29399/npa.24890. eCollection 2020 Sep.
Aneuploids, copy number variations (CNVs), and single nucleotide variants in specific genes are the main genetic causes of developmental delay (DD) and intellectual disability disorder (IDD). These genetic changes can be detected using chromosome analysis, chromosomal microarray (CMA), and next-generation DNA sequencing techniques. Therefore; In this study, we aimed to investigate the importance of CMA in determining the genomic etiology of unexplained DD and IDD in 123 patients.
For 123 patients, chromosome analysis, DNA fragment analysis and microarray were performed. Conventional G-band karyotype analysis from peripheral blood was performed as part of the initial screening tests. FMR1 gene CGG repeat number and methylation analysis were carried out to exclude fragile X syndrome.
CMA analysis was performed in 123 unexplained IDD/DD patients with normal karyotypes and fragile X screening, which were evaluated by conventional cytogenetics. Forty-four CNVs were detected in 39 (39/123=31.7%) patients. Twelve CNV variant of unknown significance (VUS) (9.75%) patients and 7 CNV benign (5.69%) patients were reported. In 6 patients, one or more pathogenic CNVs were determined. Therefore, the diagnostic efficiency of CMA was found to be 31.7% (39/123).
Today, genetic analysis is still not part of the routine in the evaluation of IDD patients who present to psychiatry clinics. A genetic diagnosis from CMA can eliminate genetic question marks and thus alter the clinical management of patients. Approximately one-third of the positive CMA findings are clinically intervenable. However, the emergence of CNVs as important risk factors for multiple disorders increases the need for individuals with comorbid neurodevelopmental conditions to be the priority where the CMA test is recommended.
非整倍体、拷贝数变异(CNV)以及特定基因中的单核苷酸变异是发育迟缓(DD)和智力残疾障碍(IDD)的主要遗传病因。这些基因变化可通过染色体分析、染色体微阵列(CMA)和新一代DNA测序技术检测出来。因此,在本研究中,我们旨在调查CMA在确定123例患者不明原因的DD和IDD的基因组病因方面的重要性。
对123例患者进行了染色体分析、DNA片段分析和微阵列检测。作为初始筛查测试的一部分,对外周血进行了常规G带核型分析。进行了FMR1基因CGG重复数和甲基化分析以排除脆性X综合征。
对123例核型正常且脆性X筛查阴性的不明原因IDD/DD患者进行了CMA分析,这些患者通过传统细胞遗传学进行了评估。在39例(39/123 = 31.7%)患者中检测到44个CNV。报告了12例意义未明的CNV变异(VUS)(9.75%)患者和7例CNV良性(5.69%)患者。在6例患者中确定了一个或多个致病性CNV。因此,发现CMA的诊断效率为31.7%(39/123)。
如今,基因分析在精神科门诊就诊的IDD患者评估中仍非常规项目。CMA的基因诊断可以消除基因疑问,从而改变患者的临床管理。大约三分之一的CMA阳性结果在临床上是可干预的。然而,CNV作为多种疾病重要危险因素的出现,增加了对患有合并神经发育疾病的个体进行CMA检测的必要性,应将其作为优先考虑对象。